Kintara Therapeutics (KTRA) Stock Price, News & Analysis

Company Overview

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $0.16 to $0.19
• 50-Day Range: $0.16 to $0.29
• 52-Week Range: $0.08 to $4.59
• Volume: 2.80 million shs
• Average Volume: 10.44 million shs
• Market Capitalization: $9.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Kintara Therapeutics Stock Analysis - MarketRank™

Kintara Therapeutics scored higher than 4% of companies evaluated by MarketBeat, and ranked 963rd out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Kintara Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Kintara Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kintara Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.15% of the outstanding shares of Kintara Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Kintara Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kintara Therapeutics has recently decreased by 22.22%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kintara Therapeutics does not currently pay a dividend.

Dividend Growth

Kintara Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.15% of the outstanding shares of Kintara Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Kintara Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kintara Therapeutics has recently decreased by 22.22%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Kintara Therapeutics this week, compared to 0 articles on an average week.

Search Interest

Only 3 people have searched for KTRA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Kintara Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kintara Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.20% of the stock of Kintara Therapeutics is held by insiders.

Percentage Held by Institutions

Only 0.62% of the stock of Kintara Therapeutics is held by institutions.

KTRA Stock Analysis - Frequently Asked Questions

How have KTRA shares performed this year?

Kintara Therapeutics' stock was trading at $0.1696 at the beginning of the year. Since then, KTRA shares have increased by 2.6% and is now trading at $0.1740.
View the best growth stocks for 2024 here.

How were Kintara Therapeutics' earnings last quarter?

Kintara Therapeutics, Inc. (NASDAQ:KTRA) released its quarterly earnings results on Monday, November, 15th. The company reported ($8.50) EPS for the quarter, missing analysts' consensus estimates of ($7.00) by $1.50.

When did Kintara Therapeutics' stock split?

Shares of Kintara Therapeutics reverse split before market open on Monday, November 14th 2022. The 1-50 reverse split was announced on Monday, November 14th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 14th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Kintara Therapeutics?

Shares of KTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Kintara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kintara Therapeutics investors own include Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Fortress Biotech (FBIO), Immunic (IMUX) and Miragen Therapeutics (MGEN).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 9/20/2024
• Next Earnings (Estimated): 9/23/2024
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:KTRA
• CUSIP: N/A
• CIK: 1498382
• Web: www.kintara.com
• Phone: (858) 350-4364
• Fax: 604-608-5685
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($4.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-14,650,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -257.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.04
• Quick Ratio: 5.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($5.86) per share
• Price / Book: -0.03

Miscellaneous

• Outstanding Shares: 55,305,000
• Free Float: 55,194,000
• Market Cap: $8.98 million
• Optionable: Not Optionable
• Beta: 0.81